Changsha, China, July 22, 2024 - Huateng Pharma, a global leader in PEG derivatives and a CDMO for APIs and intermediates, proudly announces the launch of its latest innovation, Y-Shape PEG NHS. This advanced Succinimidyl Carboxymethyl Ester branched 2ARM PEG is designed to react efficiently with lysine amino groups on proteins or other biologics, providing a swift solution for amine PEGylation.
PEGylation, the process of covalently attaching a PEG derivative to molecules, significantly improves their water solubility and biocompatibility—critical benefits for protein drug development. The Y-Shape PEG NHS ester dissolves easily in aqueous buffers, facilitating straightforward and effective modification of proteins and other biological agents containing lysines.
Compared to linear PEG NHS esters, Huateng Pharma’s Y-Shape PEG NHS esters offer increased selectivity for more sterically accessible amines under typical PEGylation conditions, thanks to their unique bulky structure. This selectivity allows for protein PEGylation to be completed in less than one hour under the recommended reaction conditions, making it a time-efficient and reliable option for researchers and developers.
"Our new Y-Shape PEG NHS esters represent a significant advancement in protein PEGylation, offering greater selectivity and efficiency," said Sonia Lee, Head of Business Development at Huateng Pharma. "This innovation underscores our commitment to providing cutting-edge solutions that meet the evolving needs of the biopharmaceutical industry."
For more information about Y-Shape PEG NHS and other innovative products from Huateng Pharma, please visit https://us.huatengsci.com or contact our sales team at sales@huatengusa.com.
Contact: Huateng Pharma
Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone,
Changsha City, Hunan Province, P.R. China
Telephone: +86 731 89916275
Email: sales@huatengusa.com
Website: https://us.huatengsci.com
About Huateng Pharma
Huateng Pharma is a world-leading supplier of PEG derivatives and a CDMO for APIs and intermediates, offering services from R&D lab supply to commercial production. We provide comprehensive support for the biopharmaceutical industry with our advanced PEG technology, dedicated to advancing biopharmaceuticals through innovation and excellence.